Tiziana Life Sciences Ltd. (TLSA), a clinical-stage biopharmaceutical company, announced Monday positive six-month clinical results in multiple sclerosis patients treated with intranasal Foralumab.
16.10.2023 - Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.Data was presented at ECTRIMS . Seite 1